Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House (8th floor) 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Angela Timoney FRPharmS
NHS SCOTLAND

Statement of Advice:

denosumab (Xgeva®) 120 mg solution for injection (No: 752/11)

Amgen

04 November 2011

ADVICE: in the absence of a submission from the holder of the marketing authorisation

denosumab (Xgeva®) is not recommended for use within NHS Scotland.

Indication: Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumours.

NICE (National Institute for Health and Clinical Excellence) is currently undertaking a multiple technology appraisal (MTA) that includes the use of denosumab in this indication. However due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman,
Scottish Medicines Consortium

Published 12 December 2011